Answers are grounded in this paper and cite their sources.
Type 2 diabetes mellitus (T2DM) is a chronic disease with a rising prevalence worldwide that is characterized by hyperglycemia and insulin resistance.Metformin, which improves blood glucose levels and insulin sensitivity, is considered the first-line therapy for T2DM.In patients with T2DM who are overweight or obese, glucagonlike peptide 1 (GLP-1) and dual GLP-1/gastric inhibitory peptide (GIP) agonists are used as adjunct or alternative therapies given their dual benefits for insulin sensitivity and weight loss.Beyond the metabolic implications of T2DM medications, these agents also have hormonal and immunologic effects that may impact dermatologic diseases (eg, psoriasis, hidradenitis suppurativa [HS]).In this review, we highlight the dermatologic adverse effects and potential therapeutic benefits of metformin as well as GLP-1 and GLP-1/GIP agonists.T ype 2 diabetes mellitus (T2DM) is a chronic disease characterized by uncontrolled hyperglycemia.Over the past few decades, its prevalence has steadily increased, now affecting approximately 10% of adults worldwide and ranking among the top 10 leading causes of death globally.1 The pathophysiology of T2DM involves persistent hyperglycemia that drives insulin resistance and a progressive decline in insulin production from the pancreas.2 Medical management of this condition aims to reduce blood glucose levels or enhance insulin production and sensitivity.Aside from lifestyle modifications, metformin is considered the first-line treatment for glycemic control according to the 2023 American Association of Clinical Endocrinology's T2DM management algorithm.3 These updated guidelines stratify adjunct treatments by individualized glycemic targets and patient needs.For patients who are overweight or obese, glucagonlike peptide 1 (GLP-1) and dual GLP-1/ gastric inhibitory polypeptide (GIP) agonists are the preferred adjunct or second-line treatments.3 In this review, we highlight the dermatologic adverse effects and potential therapeutic benefits of metformin as well as GLP-1 and GLP-1/GIP agonists. METFORMINMetformin is a biguanide agent used as a first-line treatment for T2DM because of its ability to reduce hepatic glucose production and increase peripheral tissue glucose uptake.4 In addition to its effects on glucose, metformin has been shown to have anti-inflammatory properties via inhibition of the nuclear factor κB and mammalian target of rapamycin (mTOR) pathways, leading to decreased production of cytokines associated with T helper (Th) 1 and Th17 cell responses, such as IL-17, interferon gamma (IFN-γ), and tumor necrosis factor α (TNF-α).[5][6][7] These findings have spurred interest among clinicians in the potential use of metformin for inflammatory conditions, including dermatologic diseases such as psoriasis and hidradenitis suppurativa (HS).8 Adverse EffectsMetformin is administered orally and generally is well tolerated.The most common adverse effects include gastrointestinal symptoms such as diarrhea, nausea, vomiting, and abdominal pain.9 While cutaneous adverse effects are rare, multiple dermatologic adverse reactions to metformin have been reported, 10,11 including leukocytoclastic vasculitis, [11][12][13] PRACTICE POINTS• Type 2 diabetes mellitus (T2DM) is highly prevalent in patients with various dermatologic conditions; therefore, it is important for dermatologists to understand the adverse effects of T2DM medications to optimize treatment strategies.• In addition to glycemic control and management, the hormonal and immunologic effects of T2DM medications can be leveraged to treat dermatologic conditions, particularly those associated with metabolic dysregulation.
No takes yet. Share an insight, caveat, or question.
Mayra A. Betancourt Ponce (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: